Ovarian Cancer May Begin in the Fallopian Tubes More Often Than Once Thought
Medicine has long named cancers for the organ where they are found. Ovarian cancer may be one of the clearest exceptions. Mounting evidence now points to the fallopian tubes, not the ovary itself, as the starting point for many cases of this disease.
The shift matters because ovarian cancer remains one of the deadliest gynecologic malignancies. About 21,000 women are diagnosed each year in the United States, and more than 12,000 die from the disease. A major reason is late detection: roughly three-quarters of women are diagnosed only after the cancer has already spread. Early symptoms can be subtle enough to miss, including bloating, urinary urgency, and feeling full quickly.
The biology offers a plausible explanation for why the ovary may so often be the site of discovery rather than origin. The fimbriae, the finger-like projections at the end of the fallopian tubes, sit next to the ovary and can shed abnormal cells directly onto its surface. By the time cancer is recognized, the ovary may contain the visible tumor even when the malignant process began elsewhere.
Why High-Risk Tubes Have Changed the Conversation
The case for a tubal origin strengthened when scientists began examining fallopian tubes removed from women at high genetic risk for ovarian cancer. Precancerous lesions repeatedly turned up in those tubes, especially in the fimbriae. Those findings pushed clinicians to rethink a disease that had long been classified by its final destination rather than its earliest biology.
Dr. Katharine Esselen, a gynecologic oncologist at Harvard-affiliated Beth Israel Deaconess Medical Center, said the proportion of ovarian cancers that begin in the tubes is not yet known with precision, but it may be as high as 80%. That estimate, while not definitive, is clinically consequential. If the earliest malignant change often starts in the tubes, prevention strategies should focus there first.
High-grade serous carcinoma is the deadliest ovarian cancer subtype and accounts for about 70% of cases. A study of nearly 86,000 women published Feb. 2, 2026, in JAMA Network Open found that removing the fallopian tubes during another pelvic surgery, while leaving the ovaries in place, was linked with a 78% lower odds of developing this subtype among average-risk women.
That is a large signal in a cancer where screening remains weak and treatment often begins late.
Dr. Esselen also pointed to other studies showing a 50% risk reduction when the tubes are completely removed. Even without a precise estimate for every subtype, the trend is biologically coherent: eliminating the tissue where precancerous change may start removes the place where malignant progression can take hold.
Prevention Is Moving Toward the Tubes, Not the Ovaries
The prevention strategy is changing in a practical way. Women with BRCA1 or BRCA2 mutations, who face much higher ovarian cancer risk, have long been advised to remove both ovaries and fallopian tubes after childbearing is complete. For average-risk women, the approach is now different.
Major medical organizations are recommending that healthy women already undergoing pelvic or abdominal surgery for another reason be offered removal of both fallopian tubes if they would otherwise remain in place. That includes operations such as hysterectomy, gallbladder removal, or appendectomy. The extra step adds minimal time and risk when it is done during an operation already planned for another indication.
The clinical logic is straightforward. If the tubes are the likely origin for many cancers, removing them opportunistically may lower future risk without forcing healthy women into a cancer-prevention surgery they do not otherwise need.
This is not the same as removing the ovaries. It is a narrower intervention aimed at a specific anatomic site with a likely carcinogenic role.
Why Ovarian Conservation Still Matters
Preserving the ovaries in average-risk women before menopause remains important because the ovaries are hormonally active. They produce hormones that support bone health, cardiovascular health, and overall menopausal stability. Removing them too early causes immediate menopause, along with hot flashes, vaginal dryness, and longer-term health consequences.
That is why elective ovary removal is not a simple preventive step for women at otherwise average risk. The benefit of reducing cancer risk must be weighed against the physiologic cost of abrupt hormonal loss. The fallopian tubes, by contrast, do not produce hormones, so their removal does not carry the same direct endocrine consequences.
The Remaining Risk Cannot Be Reduced to Zero
Even with the new emphasis on tubal removal, ovarian cancer risk does not disappear entirely. A small number of cancers likely still arise in the ovary itself. For that reason, patients should not assume that removing the fallopian tubes provides absolute protection.
The prevention model is better understood as risk reduction, not elimination. In a disease with poor screening tools and vague early symptoms, reducing the number of future cancers by even a moderate or large fraction could change the population burden over time.
Dr. Esselen predicted the strategy will gain traction in the coming years, especially as more surgeons and patients become familiar with the rationale. She described the approach as a shift from focusing only on very high-risk patients to a broader population-level prevention strategy. If uptake expands, the incidence of some ovarian cancers could fall.
The next challenge is implementation: consistent counseling before routine pelvic or abdominal surgery, careful selection of patients, and continued clarity that tubal removal lowers risk without abolishing it. The biology has already changed the conversation; the question now is how quickly surgical practice will follow.